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Results: Among 518 liver biopsies, the most frequent histological
ﬁnding was Mild Chronic Hepatitis (57.1%, n=296) followed by
moderate Chronic Hepatitis (41.5%, n=215) and Severe Chronic
Hepatitis was found in 7 patients (1.4%).
87.5% patients had grade 0-8 (mild chronic inﬂammation) accord-
ing to HAI scoring system. 56.6% (n=293) patients had no ﬁbrosis
(stage 0), 42.8% (n=222) had some degree of ﬁbrosis (stage 1-5)
and 0.6% n=3 had cirrhosis (stage 6) on liver biopsy according to
HAI scoring system.
Among those with normal ALT 63% had mild inﬂammation and 37%
had moderate to severe inﬂammation. About 54.5% of those with
high ALT also had mild inﬂammation and 45.5% had moderate to
severe inﬂammation.
Conclusion: Thus there was no statistically signiﬁcant relation-
ship between ALT levels and the severity of Inﬂammation on Liver
Biopsy (p value of 0.085)
PP-134 HCV F protein, a protein correlating with HCV
chronic infection
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Objectives: Hepatitis C virus (HCV) produces a novel protein,
known as F protein. F protein is encoded by an open reading
frame (ORF) that overlaps the core gene in the +1 frame (core
+1 ORF). In this study, we attempt to understand the biological
functions of the F protein in the pathogenesis of HCV infection.
Methods: HCV F protein, a +1 frameshifting at codon 42 followed
by a rephasing in the normal open reading frame at stop codon
144, from the genotype 1b are expressed in E. coli. Proteins from
E. coli lysates transformed with pGEX-F and the corresponding
empty vector (pGEX-4T-2) were subjected to 10% SDS-PAGE and
detected using Western blotting. The presence of antibodies
speciﬁc for the novel F protein was evaluated in the serum of
patients with an indirect ELISA.
Results: E. coli BL21 (DE3) cells harboring the plasmids were
harvested, and lyzed in SDS sample buffer and examined for the
production of aimed protein about 43kD on SDS-PAGE.
Results: of indirect ELISA carried out on 120 serum samples
from 28 acute HCV patients, 62 chronic HCV patients, 30 hepatic
cirrhosis, and 10 healthy samples. Sera of 54% (15/28) of the HCV
acute patients reacted with F protein, compared to 37 of the 62
(60%) chronic patients, and 20 of 30 (67%) liver cirrhosis infected
with HCV, and this association reached statistical signiﬁcance.
Conclusion: F protein may intimately linked to the molecular
pathogenesis in HCV-infected individuals.
PP-135 Up-regulation of HCV p7 on ASGPR1 gene
promoter
Jiang Guo*. Institute of Infectious Diseases, Beijing Ditan
Hospital, Beijing, China
Background: To investigate the transregulating effect of HCV p7
on ASGPR1 gene promoter.
Methods: Polymerase chain reaction (PCR) technique was em-
ployed to amplify the coding sequence of ASGPR1 promoter from
HepG2 genomic DNA, and the product was subcloned into pCAT3-
Basic by Kpn I and Bgl II, named pCAT3-ASGPR1p. pCAT3-ASGPR1p
was transfected into the hepatoblastoma cell line HepG2, then
cotransfected with pcDNA3.1(–)-HCV p7 by FuGENE 6 transfec-
tion reagents. The HepG2 cells transfected with pCAT3-Basic was
used as negative control. The activity of CAT in HepG2 cells
transfected was detected by a ELISA kit after 48 hours, which
reﬂected the transregulating function of pcDNA3.1(–)-HCV p7 to
ASGPR1 gene promoter.
Results: The report vector pCAT3-ASGPR1p has been constructed
and had been conﬁrmed by restriction enzyme digestion and
sequencing. The expression of CAT in HepG2 cells co-transfected
with pCAT3-ASGPR1p and pcDNA3.1(–)-HCV p7 was 7.7 times
as higher as that of pCAT3-Basic,and 2.4 as higher as that of
pCAT3-ASGPR1p.
Conclusions: HCV p7 can transregulate ASGPR1 promoter, and so
can up-regulate the expression of ASGPR1 gene.
PP-136 Liver steatosis and treatment of hepatitis C viral
infection
Gulnara Aghayeva*, Ali Hidayatov. Internal Diseases
Department, Azerbaijan State Medical University
Objectives: There has been increasing evidence indicating
metabolic disturbances in HCV infection, which would inﬂuence
to pathogenesis and treatment of chronic hepatitis C.
Methods: We compared results of therapy with pegylated
interferon-alfa plus ribavirin in 79 patients (52%-male) with
HCV. The excessive weight was estimated with body mass index
(BMI). Patients were divided into 3 groups: 1st group with BMI <
25 kg/m2 (27), 2nd group with BMI - 26-30 kg/m 2 (30), 3rd group
with BMI> 30 kg/m2 (22).
Result: After antiviral therapy 59 patients (74,6%) had achieved
sustained virologic response SVR - 68,5% in genotype 1 (37 pa-
tients) and 88% in genotypes 2 and 3 (22). In the third group
(BMI>30 kg/m2) was lowest level of SVR (55,6%). There were high
authentic differences in each group among SVR rate in patients
with and without liver steatosis (p<0.05). Patients without liver
steatosis had SVR in 91% (1st group – 84,2%, 2nd and 3rd groups
– 100%). Patients with steatosis achieved SVR in 45% (1st group
– 37,5%, 2nd group – 70,6% and 3 group – 55,6%). All patients
without liver steatosis in the third group had achieved SVR, on
the other hand just 26.3% patients with steatosis in the same
group had achieved SVR (p<0.05).
Conclusion: The presence of hepatic steatosis is risk factor in
chronic hepatitis C patients. Improvement of the results of an-
tiviral therapy correction concerning liver steatosis is necessary,
both before as well as during the treatment of viral hepatitis
C.
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Background: Hepatocyte growth factor activator (HGFA), is a
pericellular activator of hepatocyte growth factor (HGF) which
plays a potent role in liver repair after injury.
Objectives: The aims of this study were to investigate the im-
munostaining of HGFA in liver tissues from patients with hepatitis
C virus (HCV) infection and to correlate its expression with
the grade of activity, stage of ﬁbrosis and immunohistochemical
expression of transforming growth factor beta1 (TGF-β1).
Methods: Parafﬁn embedded liver sections prepared from 31
biopsies of patients with HCV-related chronic hepatitis (41±8 y)
and 20 normal healthy subjects, donors for liver transplantation
(29±7.5 y) were evaluated for grading and staging of chronic
hepatitis according to Ishak scoring system and applied for im-
munostaining with HGFA and TGF-β1. Semiquantitative analysis
of immunoreactive cells’ intensity and percentage for HGFA and
TGFβ1 were interpreted to calculate the H-score.
Results: Liver tissue from HCV related chronic hepatitis revealed
preferential distribution of HGFA around sites of injury and re-
generation. HGFA H-score correlated signiﬁcantly with the grade
of activity and stage of ﬁbrosis (p<0.01 each) and a highly
statistical signiﬁcant direct correlation between TGF-β1 H-score.
There was a high statistically signiﬁcant difference between nor-
